Stay updated with breaking news from Ondexxya. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NICE backs restricted use of Ondexxya 6th April 2021 NHS cost regulators have backed funding for Alexion s Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the gastrointestinal (GI) tract. Until now, there has been no licensed therapy to reverse FXa-associated major bleeds when treated with apixaban or rivaroxaban, which are increasingly used for the prevention and treatment of thrombotic events, such as deep vein thrombosis and pulmonary embolism, or if a patient is at high risk of a stroke due to an irregular heart rate (atrial fibrillation). ....